 |
|
Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
Ingrid H. Wolf, MD;
Lorenzo Cerroni, MD;
Kazuo Kodama, MD;
Helmut Kerl, MD
Arch Dermatol. 2005;141:510-514.
Background Surgical excision is the treatment of choice for lentigo maligna (LM), or melanoma in situ. Topical application of imiquimod, a local immune response modifier, is a novel therapeutic approach that leads to LM tumor clearance. This pilot, open-label, nonrandomized study evaluates the efficacy of imiquimod in patients with LM and other systemic problems that make them poor surgical risks.
Observations Six biopsy-proven cases of LM from 5 patients (age range, 67-80 years) in whom standard surgical therapy was contraindicated were enrolled in the study. Five tumors were located on the face and 1 on the right shoulder. Imiquimod was used as a 5% cream once a day for a maximum of 13 weeks. Immediate clinical responses and follow-up, as well as histopathologic changes and immunohistologic parameters (in 2 patients), were analyzed. The complete response rate for all LM cases was 100%. Time to complete clearing varied from 5 to 13 weeks based on both clinical and histopathologic findings. The inflammatory infiltrate following imiquimod treatment consisted of T-helper lymphocytes mixed with a significant number of cytotoxic cells and monocytes or macrophages. These results indicate that imiquimod induces a cytotoxic T-cell–mediated immune response. In all patients, erythema and erosions occurred at the treated area 2 to 4 weeks after initiation of imiquimod therapy. The patients have been followed up for 3 to 18 months without evidence of recurrences.
Conclusions Topical imiquimod appears to be an excellent therapeutic option for LM. Close evaluation of patients, including posttherapy histopathologic investigation, is essential. Imiquimod can be added to the list of therapeutic approaches for carefully selected patients with LM.
Author Affiliations: Department of Dermatology, Medical University of Graz, Graz, Austria (Drs Wolf, Cerroni, and Kerl); and Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan (Dr Kodama).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of Atypical Nevi With Imiquimod 5% Cream
Somani et al.
Arch Dermatol 2007;143:379-385.
ABSTRACT
| FULL TEXT
Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna.
Micantonio et al.
Arch Dermatol 2006;142:530-531.
FULL TEXT
The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity
Prins et al.
J. Immunol. 2006;176:157-164.
ABSTRACT
| FULL TEXT
|
